Ryan McInerney, Director, Chief Executive Officer, on April 29, 2026, sold 31,455 shares in Visa (V) for $10,699,204. Following the Form 4 filing with the SEC, McInerney has control over a total of 280,342 Class A common shares of the company, with 15,174 shares held directly and 265,168 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1403161/000140316126000081/xslF345X05/form4.xml
Steven S. Fendley, President, US Division, on April 27, 2026, sold 7,000 shares in Kratos Defense & Security Solutions (KTOS) for $431,451. Following the Form 4 filing with the SEC, Fendley has control over a total of 351,039 common shares of the company, with 351,039 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1069258/000169543426000006/xslF345X05/primary_doc.xml
Anthony Mancini, Chief Global Commercialization Officer, on April 27, 2026, sold 3,120 shares in Revolution Medicines (RVMD) for $413,129. Following the Form 4 filing with the SEC, Mancini has control over a total of 54,400 common shares of the company, with 54,400 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1628171/000161071726000158/xslF345X05/form4.xml
Daniel Patrick O'Day, Director, Chairman & CEO, on April 28, 2026, sold 10,000 shares in Gilead Sciences (GILD) for $1,291,608. Following the Form 4 filing with the SEC, O'Day has control over a total of 632,567 common shares of the company, with 632,567 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/882095/000163864326000020/xslF345X05/wk-form4_1777499620.xml